Tamaki N and Ahlholm N et al.

## Tamaki N and Ahlholm N et al. Supplemental table 1. Characteristics of probands in the derivation and validation cohort

|                                      | UCSD (derivation) cohort              |   |  | Helsinki (validation) cohort         |   |   |
|--------------------------------------|---------------------------------------|---|--|--------------------------------------|---|---|
|                                      | Probands of non-<br>NAFLD<br>(n = 73) | Probands of<br>NAFLD without<br>advanced fibrosis<br>(n = 17) | Probands of NAFLD<br>with advanced<br>fibrosis<br>(n = 66) | Probands of<br>non-NAFLD<br>(n = 46) | Probands of NAFLD<br>without advanced<br>fibrosis<br>(n = 19) | Probands of NAFLD<br>with advanced fibrosis<br>(n = 21) |
| Age (years)                          | 54 (27–62)                            | 57 (48–62)  | 63 (57–70)   | 55 (42–61)                           | 56 (51–62)  | 65 (61–67)  |
| Gender (female, n, %)                | 57 (78.1%)                            | 9 (52.9%)   | 49 (74.2%)   | 35 (76.1%)                           | 13 (68.4%)  | 9 (42.9%)   |
| Race/ethnicity                       |                                       |   |  |                                      |   |   |
| Hispanic (n, %)                      | 13 (17.8%)                            | 4 (23.5%)   | 42 (63.6%)   | 0 (0%)                               | 0 (0%)  | 0 (0%)  |
| Non-Hispanic (n, %)                  | 60 (82.2%)                            | 13 (76.5%)  | 24 (36.4%)   | 46 (100%)                            | 19 (100%)   | 21 (100%)   |
| Waist circumference                  |                                       |   |  |                                      |   |   |
| (cm)                                 | 87 (80–96)                            | 102 (95–114)  | 107 (97–115)   | 88 (79–98)                           | 106 (93–113)  | 106 (100–117)   |
| BMI (kg/m <sup>2</sup> )             | 24.6 (22–28)                          | 30.4 (29–37)  | 30.8 (37–36)   | 25.8 (23–29)                         | 32.6 (28–34)  | 31.4 (29–36)  |
| DM (n, %)                            | 3 (4.1%)                              | 8 (47.1%)   | 47 (71.2%)   | 5 (10.9%)                            | 4 (21.1%)   | 18 (85.7%)  |
| Dyslipidemia (n, %)                  | 27 (37.0%)                            | 13 (76.5%)  | 45 (68.2%)   | 19 (41.3%)                           | 14 (73.7%)  | 17 (81.0%)  |
| Hypertension (n, %)                  | 26 (35.6%)                            | 15 (88.2%)  | 54 (81.8%)   | 31 (67.4%)                           | 16 (84.2%)  | 21 (100%)   |
| AST (IU/L)                           | 21 (18–26)                            | 21 (17–24)  | 42 (34–54)   | 20 (16–25)                           | 30 (20–54)  | 41 (26–54)  |
| ALT (IU/L)                           | 17 (13–25)                            | 22 (17–31)  | 35 (26–48)   | 21 (17–29)                           | 47 (28–92)  | 39 (25–55)  |
| GGT (IU/L)                           | 17 (12–23)                            | 26 (17–35)  | 72 (45–133)  | 18 (14–24)                           | 26 (20–64)  | 58 (30–125)   |
| Glucose (mg/dl)                      | 89 (83–93)                            | 101 (90–113)  | 111 (95–147)   | 94 (89–101)                          | 104 (99–113)  | 149 (119–172)   |
| HbA1c (%)                            | 5.6 (5.5–5.9)                         | 6.1 (5.5–7.2)   | 6.3 (5.6–7.2)  | 5.3 (5.1–5.4)                        | 5.6 (5.4–6.0)   | 7.2 (6.4–7.6)   |
| HDL (mg/dl)                          | 64 (52–76)                            | 48 (39–51)  | 44 (36–54)   | 60 (50–69)                           | 44 (38–57)  | 37 (34–48)  |
| TG (mg/dl)                           | 72 (60–100)                           | 120 (88–193)  | 111 (91–148)   | 77 (55–91)                           | 139 (83–158)  | 143 (107–215)   |
| Platelet counts (10 <sup>9</sup> /L) | 242 (213–292)                         | 275 (246–325)   | 150 (96–202)   | 253 (203–281)                        | 287 (242–304)   | 178 (145–206)   |

Continuous data are shown in median (interquartile range).

NAFLD, nonalcoholic fatty liver disease; BMI, body mass index; DM, diabetes mellitus; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyl transferase; HbA1c, hemoglobin A1c, HDL, high-density lipoprotein; TG, triglyceride; UCSD, University of California San Diego